Treatment of Acute Malaria Infections: Lariam is indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae. Note: Patients with acute P. vivax malaria, treated with Lariam, are at high risk of relapse because Lariam does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with Lariam, patients should subsequently be treated with an 8-aminoquinoline derivative (eg, primaquine). Prevention of Malaria: Lariam is indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum (see INDICATIONS AND USAGE section in complete product information). GET A Quote
Dosage